Comments
AstraZeneca fuels biotech M&A with $1.3 billion Ardea buy
24.04.2012. | LONDON (Reuters) - AstraZeneca is to buy U.S. company Ardea Biosciences for $1.26 billion, giving it a new gout drug to bolster a weak pipeline in a deal that feeds a wave of M&A in the biotechnology sector....
